Pharmaceuticals, Biotechnology & Life Sciences

CEO Ryan Fukushima’s recent sale of 14,286 TEMPUS AI shares at $70 shows insider liquidity moves but may signal confidence in the company’s AI‑driven growth.

Twist Bioscience’s chief accounting officer sold 1,598 shares in a routine sell‑to‑cover move, showing steady liquidity amid growing insider trading and a bullish stock trend.

Greenland Mines CFO buys 14K shares, boosting optimism on a $2B rare‑earth valuation and 120% IRR, hinting at a hidden high‑growth gem.

CEO Troy Edward buys 100k Kura Oncology shares, boosting confidence in the biotech’s pipeline and signaling a bullish outlook.

Insider sale by Standard BioTools’ SVP Sean Mackay shows routine liquidity moves, not a confidence drop—watch the next earnings for clues.

CRINETICS CFO Schilke Tobin’s latest share purchase signals strong insider confidence amid a 174% YTD rally, hinting at upcoming oncology data that could push the stock closer to its 52‑week high.

Cypherpunk Technologies insider sale: Head of Mining Zhang Kevin sold 2 M RSUs for $3.36 M amid a 138% weekly surge. What this means for investors and insider trends.

CEO Martine A. Rothblatt’s recent 9,500‑share purchase of United Therapeutics at $512 signals renewed confidence, offering investors a potential catalyst for the stock’s upward momentum.

Insightful insider trading at EyePoint Inc.: CFO Elston George’s recent 5,000‑share sale shows balanced strategy, signaling cautious confidence in the eye‑care firm’s future.

Intercure CFO Amos exercises 590k options, signaling bullish confidence in the undervalued medical‑cannabis stock—potential upside for investors.